Reuters logo
4 months ago
BRIEF-Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call
April 25, 2017 / 2:11 PM / 4 months ago

BRIEF-Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call

April 25 (Reuters) - Biogen Inc

* Biogen says "we are working to add more assetts to our pipeline": Conf Call

* Biogen says "underlying tecfidera demand in the U.S. remains stable", and co is well poised to compete against rivals: Conf Call

* Biogen says it has maintained global MS market share, despite competition: Conf Call

* Biogen says underlying Spinraza demand in U.S. is robust, and numbers increasingly every week: Conf Call

* Biogen says 165 plans now cover Spinraza; of all insurance plans, atleast 75 percent cover Spinraza: Conf Call

* Biogen Exec says it will be closely watching the performance of roche's new MS drug Ocrevus; Biogen has a royalty deal with Roche for the drug

* Biogen CEO sees low single digit growth in MS market in remainder of 2017: Conf Call

* Biogen CFO says co will not comment on pricing plans for Biogen's MS drugs: Conf Call

* Biogen Exec says "we don't know ultimatley what the long-term durability of Spinraza is...but data so far has been enocuraging": Conf Call

* Biogen CFO says Roche's MS drug Ocrevus has negatively impacted Tysabri more than other Biogen drugs: Conf Call

* Biogen CFO says its hard to tell the kinetics of Spinraza performance, but expects adoption to ramp up going forward: Conf Call Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below